Medicare coverage of obesity drugs could raise federal spending by $35B through 2034 - CBO
Medicare coverage of weight loss drugs, if authorized, would increase federal spending by about $35B from 2026 to 2034, ...
Axios on MSN10d
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...
ThePrint11d
How semaglutide is emerging as A-Z drug, helping with diabetes, alcohol cravings & more
Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.
BioPharma Dive15d
FDA, after delay, clears Regeneron and Sanofi drug for COPD
The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi ... which includes medicines for cancer, obesity and another Sanofi-partnered drug, itepekimab, that’s in ...
Big News Network.com15d
US Food and Drug Administration approves 'Dupixent' for treatment of bronchitis
WASHINGTON, 28th September, 2024 (WAM) -- The US Food and Drug Administration (FDA) has approved French pharmaceutical company Sanofi's Dupixent, an anti-bronchitis drug for smokers. According to the ...
Daily Mail15d
Jannik Sinner's drug case is NOT over as the World Anti Doping Agency launch an appeal seeking a ban of between one to two years - after the Italian originally avoided a ...
World No1 Jannik Sinner could now face a ban of up to two years after his steroid case was appealed by the World Anti-Doping Agency. WADA said it is seeking a ban of one to two years for the US ...
Fox News16d
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
USA Today16d
This FDA-approved drug promises a new way to treat schizophrenia
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...
Business Wire16d
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
The Hill16d
FDA approves new type of schizophrenia drug
“This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed.” The drug, Cobenfy, is the first anti-psychotic drug ...
Time16d
FDA Approves the First New Schizophrenia Drug in Decades
No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
Newsweek16d
FDA Approves New Schizophrenia Drug in 70-Year First
The U.S. Food and Drug Administration has approved a new drug for schizophrenia with a new mechanism of action for the first time in over 70 years. The treatment offers hope to thousands of ...